(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 July 2013 (11.07.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/103262 A1

(51) International Patent Classification:
A61K 9/48 (2006.01) *A61K 31/495* (2006.01)
A61K 31/496 (2006.01) *A61K 31/4704* (2006.01)

(21) International Application Number:
PCT/KR2013/000057

(22) International Filing Date:
4 January 2013 (04.01.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10-2012-0001954 6 January 2012 (06.01.2012) KR

(71) Applicant: **HANMI PHARM. CO., LTD.** [KR/KR]; #893-5, Hajeo-ri, Paltan-myeon, Hwaseong-si, Gyeonggi-do 445-910 (KR).

(72) Inventors: **KWON, Taek Kwan**; 403-ho, 11, Hwasan-ro 213beon-gil, Jangan-gu, Suwon-si, Gyeonggi-do 440-825 (KR). **KIM, Dong Ho**; 202-ho, 13-9, Nambusunhwan-ro 256-gil, Gwanak-gu, Seoul 151-926 (KR). **KIM, Kyeong Soo**; Cheoncheon Prugio Apt. 113-1902, 85, Hwasan-ro, Jangan-gu, Suwon-si, Gyeonggi-do 440-710 (KR). **KIM, Yong Il**; Jinheung Apt. 147-2201, 57, Hwasan-ro, Paldal-gu, Suwon-si, Gyeonggi-do 442-872 (KR). **PARK, Jae Hyun**; Cheongmyeongmaeul Dongsin Apt. 311-404, 460, Yeongtong-ro, Yeongtong-gu, Suwon-si, Gyeonggi-do 443-737 (KR). **WOO, Jong Soo**; Cheoncheon Prugio Apt. 120-2303, 85, Hwasan-ro, Jangan-gu, Suwon-si, Gyeonggi-do 440-710 (KR).

(74) Agent: **FIRSTLAW P.C.**; Trust Tower, 275-7 Yangjae-Dong, Seocho-Ku, Seoul 137-739 (KR).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(54) **Title**: STABLE PHARMACEUTICAL FORMULATION FOR ORAL ADMINISTRATION COMPRISING LEVOCETIRIZINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND MONTELUKAST OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF



(57) **Abstract**: The present invention relates to a pharmaceutical formulation for oral administration for preventing or treating allergic rhinitis or asthma, which comprises: (a) a first particle part comprising levocetirizine or a pharmaceutically acceptable salt thereof and an organic acid; and (b) a second particle part comprising montelukast or a pharmaceutically acceptable salt thereof. The pharmaceutical formulation according to the present invention comprises an organic acid as a stabilizing agent, which can effectively inhibit the production of levocetirizine and montelukast related substances, and thus, show good stability.

WO 2013/103262 A1